During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat ovarian cancer, non-small cell lung cancer and ...

Novo Nordisk’s Rybelsus is an oral semaglutide, approved for treating type 2 diabetes. Image credit: JHVEPhoto / Shutterstock. Novo Nordisk plans to file a label expansion for Rybelsus (oral ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Find Therapeutics has dosed the first subject in a Phase I trial of FTX-101 as a potential treatment for chronic optic ...

Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection ...

The RightAI platform aims to assist clinicians in selecting the right patients for clinical trials and make precise treatment ...

A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient ...

Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948 for Waldenstrom's ...